Current Trials
ECHO Open to Accrual Clinical Trials
Updated: 12/19/22
| Bladder / Urothelial IMMU-132-06 A Phase II Open-Label study of IMMU-132 in Metastatic Urothelial Cancer after failure of Platinum-Based regimen or Anti-PD-1/PD-L1 based Immunotherapy Breast GS-US-592-6173 / Ascent-04 A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s choice and Pembrolizumab in Patients with Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, whose Tumors Express PD-L1 GS-US-592-6238 / Ascent-03 A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients with Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated with Anti-PD(L)1 Agents in the Early Setting Whose Tumors do Express PD-L1 ML43171 A Phase III, randomized, Open-Label, multicenter study evaluating the efficacy and safety of Giredestrant plus Everolimus compared with Exemestane plus Everolimus in patients with estrogen receptor-positive, HER2-Negative, locally advanced or Metastatic Breast Cancer Colorectal Metastatic ART-123.PN101 A Double-Blind, Placebo-Controlled, Randomized, Dose-Escalating, Multi-Center, Phase 1 Study to Assess the Safety and Tolerability of ART-123 in Combination with Leucovorin/5-Fluorouracil/Oxaliplatin and Bevacizumab in Metastatic Colorectal Cancer patients CA224-123 A Phase 3, Randomized, Open-label (Sponsor Blinded) Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants with Later-lines of Metastatic Colorectal Cancer Gritstone / GO-010 A Phase 2/3, randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination with Immune Checkpoint Blockade for Patients with Metastatic Colorectal Cancer MRT 849-010 / Krystal-10 A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy Lung JZP 712-402 Emerge 402: Phase IV Observational Study to Collect Safety and Outcome data in Real-World Setting in Adult Patients with Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca Alchemist Trials Adjuvant Trials for completely resected patients EGFR or ALK positive A151216 Adjuvant Lung Cancer enrichment marker identification and sequencing trial (Alchemist) E4512 A phase III double-blind trial for surgically resected early stage Non-Small Cell Lung cancer: Crizotinib versus Placebo for pateints with tumors harboring the Anaplastic Lymphoma Kinase (ALK) fusion protein First Line Metastatic GS-US-626-6216 / Star-121 A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimaband Domvanalimab in Combination with Chemotherapy versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with no Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations Mirati 849-007 A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced non-Small Cell Lung Cancer with KRAS G12C Mutation TAK-788-3001 A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutation Second Line Metastatic GSK 213410 A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants with Advanced Nonsmall Cell Lung Cancer who have Progressed on Prior Anti PD (L)1 Therapy and Chemotherapy (Costar Lung) Lymphoma D8227C00001 / ACE-LY-312 / Escalade A phase 3, Randomized, Double-Blind, Placebo-controlled study of Acalabrutinib in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects 65 years or younger with previously untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma Myeloma TIG-007 Study of EOS884448 alone, and in combination with Iberdomide with or without Dexamethasone, in participants with relapsed or refactory Multiple Myeloma Prostate Cancer AMPLITUDE / 67652000PCR3002 A Phase 3 Randomized, Placebo-controlled, Double-Blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone versus Abiraterone Acetate and Prednisone for the treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC). LAE201INT2101 A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone plus Afuresertib in Patients with Metastatic Castration-Resistant Prostate Cancer Following Standard of Care Treatment Solid Tumors JZP712-201 / Emerge-201 A Phase 2, Multicenter, Open-Label Study of Lurbinectedin Efficacy and Safety in Participants with Advanced or Metastatic Solid Tumors PBI-200-101/TIME-Tempus Trial A Phase 1-2 Study of PBI200 in Subjects with NTRK-Fusion-Positive Advanced or Metastatic Solid Tumors SGNLVA-005 Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors Supportive Care Bespoke (Natera) BESPOKE Study of ctDNA Guided Immunotherapy ESR 22-21698 (EIMPRIS) Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2 Infection in Immuno-Suppressed Cancer Patients FRNM-008 (Freenome) A Case Control Study for the Development of Multiomics Blood Test for Cancer Screening Ready 1 / CUSA-081-HEM-01 /YYA36723 Phase 3, Randomized, Double-Hem-Blind, Active and Placebo Controlled Study on the use of CUSA-081 for Dysfunctional Central Venous Access Devices (CVADs) Seer – 020102 (SeerPro) A Prospective Blood Sample Collection Study to Evaluate a Panel of Protein-based Biomarkers THR-CS-001 / THRIVE / DETECT-ASCEND 2 ***Only Thyroid, Ovarian, Uterine and Bladder Cohorts Open*** Exact Sciences Thrive LLC / Detecting Cancers Earlier Through Elective Plasma-Based CancerSEEK Testing – Ascertaining Serial Cancer Patients to Enable New Diagnostic II (DETECT-ASCEND 2) |
To learn about our newest study on biomarker testing, click here.
To learn about our newest study on bladder cancer, click here.
For more information on clinical trials, please contact Dr. Susan Johnson, Director of Research sjohnson@echoct.com or 860-886-8362.